14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IBRX vs PVLA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, ImmunityBio, Inc. (IBRX) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBRX carries a Unified Composite Score of 53.2/100 (HOLD) at $6.03 (66.7x Forward P/E, -150.2% operating margin), whereas PVLA carries 48.9/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: IBRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile PVLA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IBRX vs PVLA Key Questions & Quantitative Answers
As of Nov 16, 2026, ImmunityBio, Inc. (IBRX) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBRX carries a Unified Composite Score of 53.2/100 (HOLD) at $6.03 (66.7x Forward P/E, -150.2% operating margin), whereas PVLA carries 48.9/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: IBRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile PVLA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IBRX leads the Growth & Scale pillar: IBRX posts +52.3% YoY revenue growth and +0.0% YoY earnings growth on $183M TTM revenue (98.8% gross margin, -150.2% operating margin), compared with PVLA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IBRX cumulative revenue shifted +1000.0% while PVLA shifted +33.3%. In operating R&D and SG&A reinvestment, IBRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PVLA.
IBRX screens cheaper on headline valuation multiples. IBRX trades at 66.7x Forward P/E, 66.7x Trailing P/E, N/M PEG, and 39.9x EV/Revenue (unreported FCF margin), whereas PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBRX (0.0% ROE) versus PVLA (-63.4% ROE) capital efficiency.
In options market volatility and institutional positioning, IBRX carries 93.0% implied volatility (16th %ile, Compressed (<25th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 103% Vol realized risk). By comparison, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.